Oral Glutamine Increases Circulating GLP-1, Glucagon and Insulin Levels in Lean, Obese and Type 2 Diabetic Subjects

Glutamine effectively increases circulating GLP-1, GIP and insulin levels in vivo and may represent a novel therapeutic approach to stimulating insulin secretion in obesity and type 2 diabetes.

Keywords: GLP-1, GIP, glucagon, insulin secretion, glutamine

Source: Oral Glutamine Increases Circulating GLP-1, Glucagon and Insulin Levels in Lean, Obese and Type 2 Diabetic Subjects

Adequate Vitamin B12 and low Homocysteine Levels may slow  progression of PD

Source: Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson’s Disease

Background: In moderately advanced Parkinson’s disease (PD), low serum vitamin B12 levels are common and are associated with neuropathy and cognitive impairment. However, little is known about B12 in early PD.

Objective: To determine the prevalence of low vitamin B12 status in early PD and whether it is associated with clinical progression.

Methods: We measured vitamin B12 and other B12 status determinants (methylmalonic acid, , and holotranscobalamin) in 680 baseline and 456 follow-up serum samples collected from DATATOP participants with early, untreated PD. Borderline low B12 status was defined as serum B12 <184 pmol/L (250 pg/mL), and elevated homocysteine was defined as >15 µmol/L. Outcomes included the UPDRS, ambulatory capacity score (sum of UPDRS items 13-15, 29&30), and MMSE, calculated as annualized rates of change.

Results: At baseline, 13% had borderline low B12 levels, 7% had elevated homocysteine, whereas 2% had both. Elevated homocysteine at baseline was associated with worse scores on the baseline MMSE. Analysis of study outcomes showed that compared with the other tertiles, participants in the low B12 tertile (<234 pmol/L; 317 pg/mL) developed greater morbidity as assessed by greater annualized worsening of the ambulatory capacity score. Elevated homocysteine was associated with greater annualized decline in MMSE (−1.96 vs. 0.06; P = 0001). Blood count indices were not associated with B12 or homocysteine status. Conclusions: In this study of early PD, low B12 status was common. Low B12 at baseline predicted greater worsening of mobility whereas elevated homocysteine predicted greater cognitive decline. Given that low B12 and elevated homocysteine can improve with vitamin supplementation, future studies should test whether prevention or early correction of these nutritionally modifiable conditions slows development of disability. © 2018 International Parkinson and Movement Disorder Society Supporting Informatio

probiotics Bacillus subtilis PXN® 21® eliminates alpha-synuclein aggregates, possible PD treatment

Article in Cell megazine:

where to buy:


Exenatide, a GLP-1 receptor agonist licensed to treat type 2 diabetes, and recently shown to be associated with reduced severity of PD



1 completed research findings

Exenatide had positive effects on practically defined off-medication motor scores in Parkinson’s disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson’s disease, and effects on everyday symptoms should be examined in longer-term trials.

Supplement alternative – Glutamine >> 


 A Report of 10 cases of Parkinson’s Disease cured by Xifengzhizhan pills and Xifengzhizhan capsules, Wang Weifan

A Report of 10 cases of Parkinson’s Disease cured by Xifengzhizhan pills and Xifengzhizhan capsules, Wang Weifan


treatment based on traditional Chinese herbal medicine



LSVT voice therapy

we suggest that LSVT encourages acceptance of and comfort with increased loudness and the ability to self-monitor vocal loudness. Addressing this apparent sensory mismatch between vocal effort and vocal output may contribute to generalization and maintenance of treatment effects. Finally, treatment that is simple, redundant, and intensive may help accommodate the processing speed, memory, and executive function deficits observed in some individuals with IPD. It may also promote overlearning and internalization of the vocal effort required for normal loudness


Our 15 years of research have generated the first short- and long-term efficacy data for speech treatment (Lee Silverman Voice Treatment; LSVT/LOUD) in Parkinson’s disease. We have learned that training the single motor control parameter amplitude (vocal loudness) and recalibration of self-perception of vocal loudness are fundamental elements underlying treatment success. This training requires intensive, high-effort exercise combined with a single, functionally relevant target (loudness) taught across simple to complex speech tasks. We have documented that training vocal loudness results in distributed effects of improved articulation, facial expression, and swallowing. Furthermore, positive effects of LSVT/LOUD have been documented in disorders other than Parkinson’s disease (stroke, cerebral palsy). The purpose of this article is to elucidate the potential of a single target in treatment to encourage cross-system improvements across seemingly diverse motor systems and to discuss key elements in mode of delivery of treatment that are consistent with principles of neural plasticity.




The Use of Dental Almagam Fillings

The World Health Organization has come to the conclusion that a global ban on the use of amalgam will be problematic for economic and logistical reasons. So it has recommended a gradual decrease in the use of amalgam.

WHO Mercury and Health

A document published on the FDA website, the U.S. Food and Drug Administration, describes the dangers of amalgam in an effort to encourage and persuade the head of the administration to ban the use of amalgam. The document specifically mentions amalgam as a cause of neurological diseases.

A review with an impressive scope (78 pages, about 500 references), on the FDA website, outlines the ways mercury from a dental source causes various chronic diseases.

Testimonials were given to the FDA on the harm caused by mercury from a dental source.

Studies on the toxicity of amalgam:

Review of 70 studies on toxicity of amalgam

Dental Amalgam Mercury Solutions

An information video explains several studies on the seepage of mercury from filling into the body. At minute 4:16 the video shows an experiment on monkeys. Fillings with mercury were marked with a radioactive isotope. Within about 30 days of the filings being inserted a significant accumulation of mercury in the kidneys, intestines, and other organs was demonstrated with the use of an MRI.

Whole-body imaging of the distribution of mercury released from dental fillings into monkey tissues.

Mercury detox, with and without infusion with chelating agent, here (H).

Rehabilitation of Mitochondria by Lipid Replacement

According to Dr. Garth Nicholson, with prolonged mycoplasma viral infections, the pathogen penetrates cells and causes mitochondrial damage. The phenomenon is typical in a number of chronic diseases (for the infection as a cause of chronic diseases go here), as a result of cancer treatments, and as a result of aging. Declined mitochondrial function causes fatigue and other damage.

For the role of mitochondria in idiopathic Parkinson’s go here, and here.

The above treatment was originally developed for anti-aging.

LRT – Lipid Replacement Therapy

Treatment is by capsules containing lipids needed to repair the mitochondria. Capsules contain a higher concentration of lipids than found in food. The capsules preserve their integrity as they travel through the digestive system. In essence, it is a nutritional supplement.

A short explanation of LRT:

As discussed in the video, it can be assumed that a diet based on unprocessed and uncooked organic food will have good results.

Here is a study showing a significant improvement in mitochondrial function after taking an NT Factor supplement pack for 12 weeks.

NT Factor Contents:

NTFactor® is a nutrient complex that is extracted and prepared using a proprietary process that protects lipids from oxidation. In addition, nutrients, vitamins and probiotic microorganisms are added to the preparation. It contains the following ingredients: Glycophospholipids: polyunsaturated phosphatidylcholine, other polyunsaturated phosphatidyl lipids, glycolipids and other lipids such as cardiolipin and sterol lipids. Probiotics: Bifido bacterium, Lactobacillus acidophilus and Lactobacillus bacillus in a freeze-dried, microencapsulated form with appropriate growth nutrients. Food Supplements, Vitamins and Growth Media: bacterial growth factors to support probiotic growth, including defatted rice bran, arginine, beet root fiber extract, black strap molasses, glycine, magnesium sulfate, para-amino-benzoate, leek extract, pantethine (bifidus growth factor), taurine, garlic extract, calcium borogluconate, artichoke extract, potassium citrate, calcium sulfate, spirulina, bromelain, natural vitamin E, calcium ascorbate, alpha-lipoic acid, oligosaccharides, vitamin B-6, niacinamide, riboflavin, inositol, niacin, calcium pantothenate, thiamin, vitamin B-12, folic acid, chromium picolinate.

Additional Information and Purchase:

Caloric vestibular stimulation (CVS) relieved motor and non-motor symptoms(PD)

repeated sessions of caloric vestibular stimulation (CVS) relieved motor and non-motor symptoms associated with Parkinson’s disease (PD).


Caloric vestibular stimulation involves the transmission of either warm or cool temperature, usually via water or air, from the external ear canal to the vestibular organs located in the adjacent labyrinth


Future: The A1 astrocyte paradigm: New way for pharmacological intervention in neurodegeneration – PubMed

We recently demonstrated that NLY01, a novel glucagon-like peptide-1 receptor agonist, exerts neuroprotective effects in two mouse models of PD in a glia-dependent manner. NLY01 prevented microglia from releasing inflammatory mediators known to convert astrocytes into a neurotoxic A1 reactive subtyp …

Source: The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration – PubMed